IMMAGINA Biotechnology s.r.l. proudly holds the exclusive research use license for the groundbreaking nano-tRNAseq technology, originally developed by the Novoa Lab at the Centre for Genomic Regulation in Barcelona, Spain and introduced in Nature Biotechnology in 20231

nano-tRNAseq marks a significant milestone in tRNA and translatomics research by enabling comprehensive sequencing of tRNA molecules in their full-length, native state, allowing for quantification of tRNA abundance and detection of tRNA modifications. nano-tRNAseq technology empowers researchers to easily pinpoint tRNA isoforms and post-translational modifications, offering deeper understanding of the intricate workings of these fundamental cellular components.

1. Lucas M, et al. (2023) Nature Biotechnology. 42(1):1-15. doi 10.1038/s41587-023-01743-6.


Immagina has improved the published methods for this technology to offer a unique and comprehensive service that includes multiplexing, comprehensive quality control, and extensive bioinformatics reporting.  Contact us for early access to the nano-tRNAseq platform and ask about special introductory rates.

>>> Download publication


  • Expand translatome studies
  • Quantify tRNA abundance;
  • Identify tRNA modifications
  • Explore ribosome-embedded tRNA Perform codon-anticodon analysis
  • Maximize drug discovery efforts
  • Investigate tRNA distribution in tissues and fluids